LCGC
IBRX icon

Legacy Capital Group California’s ImmunityBio IBRX Stock Holding History

Legacy Capital Group California’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.9M Buy
+446,000
New +$3.38M 1.18% 11

Other funds holding IBRX

DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
SSWM
Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PL
Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MWM
MFG Wealth Management Indianapolis, Indiana $140M AUM 44.72% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
DKCM
Davidson Kahn Capital Management Sherman Oaks, California $233M AUM 19.14% 1-Year Est. Return

Legacy Capital Group California's IBRX Position: Q2 2026 in Review

Legacy Capital Group California opened a new position in ImmunityBio (IBRX) in Q2 2026: 446,000 shares worth $3.9M. The stake represents 1.18% of the portfolio and ranks #11 among its holdings.

122 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Legacy Capital Group California held 446,000 shares of ImmunityBio worth $3.9M as of Q2 2026.
  • ImmunityBio was a new Legacy Capital Group California position in Q2 2026.
  • ImmunityBio made up 1.18% of Legacy Capital Group California's portfolio in Q2 2026, its #11 holding.
  • 122 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Legacy Capital Group California's 13F filing for Q2 2026, filed 29 Jul 2026.